1. Home
  2. ANAB vs PRCH Comparison

ANAB vs PRCH Comparison

Compare ANAB & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • PRCH
  • Stock Information
  • Founded
  • ANAB 2005
  • PRCH 2012
  • Country
  • ANAB United States
  • PRCH United States
  • Employees
  • ANAB N/A
  • PRCH N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • PRCH Computer Software: Prepackaged Software
  • Sector
  • ANAB Health Care
  • PRCH Technology
  • Exchange
  • ANAB Nasdaq
  • PRCH Nasdaq
  • Market Cap
  • ANAB 621.1M
  • PRCH 656.3M
  • IPO Year
  • ANAB 2017
  • PRCH N/A
  • Fundamental
  • Price
  • ANAB $23.17
  • PRCH $10.72
  • Analyst Decision
  • ANAB Buy
  • PRCH Strong Buy
  • Analyst Count
  • ANAB 10
  • PRCH 7
  • Target Price
  • ANAB $44.25
  • PRCH $8.89
  • AVG Volume (30 Days)
  • ANAB 775.6K
  • PRCH 2.3M
  • Earning Date
  • ANAB 08-04-2025
  • PRCH 08-05-2025
  • Dividend Yield
  • ANAB N/A
  • PRCH N/A
  • EPS Growth
  • ANAB N/A
  • PRCH N/A
  • EPS
  • ANAB N/A
  • PRCH N/A
  • Revenue
  • ANAB $111,872,000.00
  • PRCH $427,150,000.00
  • Revenue This Year
  • ANAB N/A
  • PRCH $4.28
  • Revenue Next Year
  • ANAB $24.39
  • PRCH $12.88
  • P/E Ratio
  • ANAB N/A
  • PRCH N/A
  • Revenue Growth
  • ANAB 387.20
  • PRCH N/A
  • 52 Week Low
  • ANAB $12.21
  • PRCH $1.05
  • 52 Week High
  • ANAB $41.31
  • PRCH $12.20
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 56.01
  • PRCH 57.01
  • Support Level
  • ANAB $22.46
  • PRCH $10.69
  • Resistance Level
  • ANAB $24.17
  • PRCH $11.68
  • Average True Range (ATR)
  • ANAB 1.72
  • PRCH 0.62
  • MACD
  • ANAB -0.01
  • PRCH -0.07
  • Stochastic Oscillator
  • ANAB 73.23
  • PRCH 60.71

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.

Share on Social Networks: